Susbstance P Levels in Children with Atopic Dermatitis
Downloads
Background: Atopic dermatitis (AD) is the most common skin disease in infants and children. AD is influenced by hereditary and environmental factors, and it is characterized by an inflammatory reaction in the skin. In developing countries, children suffering from AD are estimated around 10–20%, of which 60% of the cases persist into adulthood. Substance P is a cutaneous neuropeptide that contributes to the pathogenesis of AD. Substance P promotes the production of nerve growth factors from keratinocytes, and the release of histamine, leukotriene, or tumor necrosis factor from mast cells, which cause the growth of sensory nerve fibers, augmentation of skin inflammation, and are considered pruritogenic factors. Purpose: This study aims to determine the description of substance P in children with atopic dermatitis using a descriptive observational study with a cross-sectional approach. Methods: This is a destructive observational study with a crossectional approach samples were selected from AD patients at the Universitas Sumatera Utara Hospital. Result: The largest group of subjects were childhood (2–12 years old), there was 60%, followed by the adolescent group (12–18 years old) and the infant group (<2 years old). In the childhood group, the highest level of substance P was found in girls with a mean of 349.03 ± 146.7. On the other hand, the highest levels of substance P in the adolescent were found in males with a mean of 243.73 ± 64.57 ng/L. Conclusion: In this study, we found that the level of substance p was higher in the childhood group.
Dharmage, S.C. Lowe A. Matheson M. et al. Atopic dermatitis and the atopic march revisited. Allergy 2014; 69(1):17-27
Wang, I.-J., Wang, J.-Y., & Yeh, K.-W. Childhood atopic dermatitis in taiwan. Pediatrics & Neonatology 2016; 57(2):89–96
Nutten, Sophie. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab 2015;66(suppl 1):8–16
Lawton, Sandra. Atopic eczema in children: NICE quality standard. community practitioner 2013; 86(11):46
Botteman, Marc F. Zakiudin M. Astrid W. et al. Economic value of atopic dermatitis prevention via partiallyhydrolyzed whey-based infant formula (PHF-W) use in high-risk, non-exclusively breastfed, indonesian urban infants: result of a cost-effectiveness model. World Nutrition Journal 2018. eISSN 2580-7013
Dinulos JGH. Habif's clinical dermatology. 7th ed. Elsevier. 2021; 149-176
Zhang, Yue. Hanyi Z: Boyue current views on neuropeptides in atopic dermatitis. J. et al. Dermatol 2021;30:1588–97
Leung D.Y.M. New insights into atopic dermatitis: Role of skin barrier and immune dysregulation. Allergology International 2013;62:151161
Lotts, Tobias, Ständer, Sonja. Research in practice: Substance p antagonism in chronic pruritus. J Dtsch Dermatol 2014;12(7): 557-9
Wang, Feng Li, Zhao, Shen: ‘Prevalence and clinical features of atopic dermatitis in China'. BioMed Res Int Vol.2016.
Tay YK, Kong KH, Khoo L, et al. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br. J. Dermatol 2002; 146:101-6.
Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 national survey of children's health. J Invest Dermatol 2011; 131:67-73
Ziyab AH, Raza A, Karmaus W, et al. Trends in eczema in the first 18 years of life: result from the Isle of wight 1989 birth cohort study. Clin Exp Allergy 2010;40:1776-84.
Prameswari.R, Astari.L, Hidayati.AN, Prakoeswa.C. Efek lactobacillus plantarum terhadap imunoglobulin E serum total dan indeks scoring atopic dermatitis (SCORAD) pasien dermatitis atopi anak. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2017;29(2):91-7
Lonndahl L, Rasul A, Rahm SBL, Holst M, Johansson B, Nour HE. Tachykinin upregulation in atopic dermatitis. Immunopharmacol immunotoxicol 2018;41(1).
Lonndahl, Louise. Mikael H. Maria B. Substance P antagonist aprepitant shows no additive effect compared with standardized topical treatment alone in patients with atopic dermatitis. Acta Derm Venereol 2018; 98: 324–328.
Choi, JE. dan Nardo, A. Skin neurogenic inflammation. Semin Immunopathol 2018;40(3): 249–259.
Kim HO, Lee CH, Ahn HK, Park CW. Effects of tacrolimus ointment on the expression of substance P, nerve growth factor, and neurotrophin-3 in atopic dermatitis. Int J Dermatology 2009; 48(4): 431-8.
Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. British J Dermatology 2002; 147(1): 71-9.
Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: The role of brain-derrived neurotrophic factor and substance P. British Journal of Dermatology 2007; 157(5), 922–5.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.